Neurofibromatosis 1 Clinical Trial
Official title:
Effectiveness of a Telehealth Group for Improving Peer Relationships for Adolescents With Neurofibromatosis Type 1
This is a pilot randomized control trial of the UCLA PEERS protocol delivered via Telehealth with teens with neurofibromatosis type 1 whose parents report that they have difficulty making and keeping friends.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | August 2022 |
Est. primary completion date | September 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 17 Years |
Eligibility | Inclusion Criteria: - Physician diagnosis of neurofibromatosis type 1 - Age 12-17 - Main language spoken in the home is English - Reliable internet access - Current functional impairment in peer relationships - Teen is interested and motivated to participate Exclusion Criteria: - Main language spoken in the home is not English - Cognitive or developmental difficulties that affect reading comprehension or understanding of treatment material - Significant behavioral concerns - Other comorbid medical conditions - Major surgery in past 6 months - Prior social skills group treatment within past 6 months - Prior participation in PEERS |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin-Milwaukee | Milwaukee | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Milwaukee | NF Midwest, NF Northeast |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Peds QL (Varni et al, 2002) Parent | Change from pre- to post-test in parental ratings of QoL | within 4 weeks of PEERS completion | |
Other | Peds QL (Varni et al, 2002) Teen | Change from pre- to post-test in teen ratings of QoL | within 4 weeks of PEERS completion | |
Primary | Social Skills Improvement System - SEL (SSIS-SEL; Gresham & Elliot, 2017) Parent | Change from pre- to post-test on SSIS-SEL parent Total Standard Score (measures social functioning) | within 4 weeks of PEERS completion | |
Primary | Test of Adolescent Social SKills (TASSK: Laugeson & Frankel, 2010) | Change from pre- to post-test on total score (measures knowledge of the PEERS concepts) | within four weeks of PEERS completion | |
Primary | Social Skills Improvement System - SEL (SSIS-SEL; Gresham & Elliot, 2017) Parent | Change from pre- to 16 week followup on total score | 16 weeks following PEERS completion | |
Primary | Social Skills Improvement System - SEL (SSIS-SEL; Gresham & Elliot, 2017) Parent | Amount of change from pre- to post-test differs from change in Wait List Control group | within four weeks of PEERS completion for treatment group | |
Secondary | Social Responsiveness Scale -2 (SRS-2; Constantino, 2005) | change from pre- to post-test on Total SRS-2 completed by caregivers (measure of social impairment) | within 4 weeks following PEERS completion | |
Secondary | Social Responsiveness Scale -2 (SRS-2; Constantino, 2005) | change from pre- to 16 week followup on Total SRS-2 completed by caregivers (measure of social impairment) | 16 weeks following PEERS completion | |
Secondary | Social Skills Improvement System - SEL (SSIS-SEL; Gresham & Elliot, 2017) Teen | Change from pre- to post-test on teen self-report of social functioning | within 4 weeks of PEERS completion | |
Secondary | Social Skills Improvement System - SEL (SSIS-SEL; Gresham & Elliot, 2017) Teen | Change from pre- to 16 week followup on teen self-report of social functioning | 16 weeks following PEERS completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00352599 -
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
|
Phase 1 | |
Completed |
NCT05005845 -
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
|
Phase 2 | |
Completed |
NCT03531814 -
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
|
N/A | |
Completed |
NCT00846430 -
Medical Treatment of "High-Risk" Neurofibromas
|
Phase 2 | |
Completed |
NCT03433183 -
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
|
Phase 2 | |
Recruiting |
NCT05331105 -
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
|
Phase 2 | |
Completed |
NCT03310996 -
Non-invasive Stimulation in Neurofibromatosis Type 1
|
N/A | |
Recruiting |
NCT03406208 -
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
|
N/A | |
Recruiting |
NCT04750928 -
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06262113 -
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
|
N/A | |
Active, not recruiting |
NCT04924608 -
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
|
Phase 3 | |
Recruiting |
NCT02544022 -
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
|
||
Recruiting |
NCT04941027 -
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
|
||
Completed |
NCT02153931 -
Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
|
||
Completed |
NCT05196854 -
Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1
|
N/A | |
Active, not recruiting |
NCT01650142 -
Modifying Genes in Neurofibromatosis 1
|
N/A | |
Completed |
NCT05377008 -
Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1
|
N/A | |
Completed |
NCT04879160 -
Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
|
||
Recruiting |
NCT05735717 -
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
|
Phase 2 |